<!doctype html><html lang=en><meta charset=utf-8><meta name=generator content="Hugo 0.78.1"><meta name=viewport content="width=device-width,initial-scale=1,viewport-fit=cover"><meta name=color-scheme content="light dark"><meta name=supported-color-schemes content="light dark"><title>Henriksen 2018&nbsp;&ndash;&nbsp;Papers</title><link rel=stylesheet href=/stevengogogo/PaperNotes/css/core.min.0e6154f1fe5441faaa4f418ca1a607b9f3edbad43b1ab8782737ee279ca2c5a48c8dbe23af3340af50c91a2558bc2b55.css integrity=sha384-DmFU8f5UQfqqT0GMoaYHufPtutQ7Grh4JzfuJ5yixaSMjb4jrzNAr1DJGiVYvCtV><meta name=twitter:card content="summary"><meta name=twitter:title content="Henriksen 2018"><body><section id=header><div class="header wrap"><span class="header left-side"><a class="site home" href=/stevengogogo/PaperNotes/><span class="site name">Papers</span></a></span>
<span class="header right-side"><div class="nav wrap"><nav class=nav><a class="nav item" href=/stevengogogo/PaperNotes/categories/>Categories</a><a class="nav item" href=/stevengogogo/PaperNotes/tags/>Tags</a></nav></div></span></div><div class="site slogan"><span class=title>Collection of papers I read</span></div></section><section id=content><div class=article-container><section class="article header"><h1 class="article title">Henriksen 2018</h1><p class="article date">2020-10-23</p></section><article class="article markdown-body"><p><a href=https://sciwheel.com/work/#/items/6049576 target=_blank>Sciwheel</a></p><p><a href=https://heart.bmj.com/content/104/12/971 target=_blank>Article</a><sup id=fnref:1><a href=#fn:1 class=footnote-ref role=doc-noteref>1</a></sup></p><h2 id=anthracycline-induced-cardiotoxicity>Anthracycline-induced cardiotoxicity</h2><ul><li>Anthracyclines (doxorubicin, daunorubicin, epirubicin and idarubicin) : broad-spectrum antineoplastic
<img src=https://user-images.githubusercontent.com/40054455/86618941-535cd000-bfec-11ea-9a43-fd582efd38e4.png alt=tbl1></li><li>dose-related cardiomyocyte injury => LV dysfunction, HF. Cardiac event rates on treatment were 7%, 18% and 65% at cumulative doses of 150 mg/m2, 350 mg/m2 and 550 mg/m2, respectively</li></ul><h2 id=mechanism-of-anthracycline-cardiotoxicity>Mechanism of anthracycline cardiotoxicity</h2><p><img src=https://user-images.githubusercontent.com/40054455/86618936-522ba300-bfec-11ea-8784-cd3c44829c2a.jpg alt=fig1></p><ul><li>Increased reactive oxygen species (ROS) formation and <strong>inhibiting Topoisomerase 2β in cardiomyocytes</strong>, as well as iron accumulation inside mitochondria</li></ul><h2 id=risk-markers-for-anthracycline-cardiotoxicity>Risk markers for anthracycline cardiotoxicity</h2><ul><li>cumulative dose, female sex, African-American ancestry, age >65 years or &lt;18 years, renal failure and concomitant exposure of the heart to radiation therapy</li><li>concentrations of Top 2β in peripheral blood leucocytes: low = more resistant to anthracycline cardiotoxicity</li><li>The hiPSC-CMs from patients who developed LVEF depression exhibited increased cell death and ROS production following in vitro doxorubicin challenge</li></ul><h2 id=monitoring-for-cardiotoxicity>Monitoring for cardiotoxicity</h2><h3 id=lvef-and-global-longitudinal-strain>LVEF and global longitudinal strain</h3><ul><li>LVEF decrease of >10 percentage points from baseline to a value &lt;53% on repeat confirmatory echocardiographic imaging</li><li>Baseline LV dysfunction is a strong marker for developing heart failure complications with anthracycline</li></ul><h3 id=cardiac-biomarkers>Cardiac biomarkers</h3><ul><li>Cardiac troponin I (cTnI) and cardiac troponin T</li></ul><h2 id=prevention-and-treatment-of-cardiotoxicity>Prevention and treatment of cardiotoxicity</h2><h3 id=anthracycline-derivatives-and-infusion-protocols>Anthracycline derivatives and infusion protocols</h3><ul><li>Reducing the cumulative anthracycline dose</li><li>Liposomal encapsulation: modifies tissue distribution, but expensive</li></ul><h3 id=dexrazoxane-drz>Dexrazoxane (DRZ)</h3><ul><li>DRZ is taken up rapidly by the myocardium following infusion and competes with ATP-binding sites on <strong>Top 2β</strong></li><li>Concerns about less effective treatment in children: restricted use in adults with metastatic breast cancer receiving <strong>higher cumulative anthracycline dose</strong></li></ul><h3 id=angiotensin-inhibition-and-β-blockade>Angiotensin inhibition and β-blockade</h3><ul><li>decline in LVEF => ACEi/ARB and β-blockers</li><li>Primary prevention with β-blockade, ACEi and ARBs? Under studies</li></ul><h3 id=primary-prevention-with-statins>Primary prevention with statins</h3><ul><li>More research is needed</li></ul><h2 id=conclusions>Conclusions</h2><ul><li>Anthracycline chemotherapy remains an important and effective treatment for breast cancer, haematological malignancies and sarcoma</li><li>cardiotoxicity is dose-dependent</li><li>Testing: LVEF, cTnI</li><li>Cardioprotective therapies: DRZ, ACEi/ARB and β-blockers</li></ul><h2 id=references>References</h2><section class=footnotes role=doc-endnotes><hr><ol><li id=fn:1 role=doc-endnote><p>Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart 2018;104(12):971-977. doi:10.1136/heartjnl-2017-312103. <a href=#fnref:1 class=footnote-backref role=doc-backlink>&#8617;&#xfe0e;</a></p></li></ol></section></article><section class="article author"><p class=name>Shao-Ting Chiu</p><div class=details><a class=item href=https://github.com/stevengogogo target=_blank><span class="iconfont icon-github"></span>&nbsp;stevengogogo</a></div></section></div><div class="article bottom"><section class="article navigation"><p><a class=link href=/stevengogogo/PaperNotes/posts/hettling-2011/><span class="iconfont icon-article"></span>Hettling 2011</a></p><p><a class=link href=/stevengogogo/PaperNotes/posts/heiske-2017/><span class="iconfont icon-article"></span>Heiske 2017</a></p></section></div></section><section id=footer><div class=footer-wrap><p class=copyright>Papers</p><p class=powerby><span>Powered&nbsp;by&nbsp;</span><a href=https://gohugo.io target=_blank>Hugo</a><span>&nbsp;&&nbsp;</span><a href=https://themes.gohugo.io/hugo-notepadium/ target=_blank>Notepadium</a></p></div></section><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/katex@0.11.1/dist/katex.min.css integrity=sha384-zB1R0rpPzHqg7Kpt0Aljp8JPLqbXI3bhnPWROx27a9N0Ll6ZP/+DiW/UqRcLbRjq crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.11.1/dist/katex.min.js integrity=sha384-y23I5Q6l+B6vatafAwxRu/0oK/79VlbSz7Q9aiSZUvyWYIYsd+qj+o24G5ZU2zJz crossorigin=anonymous></script><script defer src=https://cdn.jsdelivr.net/npm/katex@0.11.1/dist/contrib/auto-render.min.js integrity=sha384-kWPLUVMOks5AQFrykwIup5lo0m3iMkkHrD0uJ4H5cjeGihAutqP0yW0J6dpFiVkI crossorigin=anonymous onload=renderMathInElement(document.body);></script></body></html>